Cureus · 2026
From Needle to Sachet: Fosfomycin Versus Amikacin for Cystoscopy Prophylaxis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Quadir Uvaisullah, Para Sajad A, Malik Sajad A, Hamid Arif, Khawaja Abdul R, Mehdi Saqib, Arsalan Syed Shakeeb, Raina Aamir B, Kannan Gokul, Bhat Omar Mukhtar
Аннотация
BACKGROUND: Antibiotic prophylaxis is commonly administered before outpatient cystoscopic procedures (CPE). This study compared the efficacy and safety of parenteral amikacin and oral fosfomycin used as prophylactic agents before outpatient cystoscopy.
METHODS: This retrospective comparative observational study included adult patients undergoing outpatient CPE at a tertiary care center between October 2024 and November 2025. Patients received either a single intravenous dose of amikacin (15 mg/kg) or a single oral dose of fosfomycin trometamol (3 g) before the procedure, according to institutional practice. The primary outcome was the incidence of symptomatic urinary tract infection (UTI) within 14 days following CPE. Secondary outcomes included culture-positive UTI and adverse drug reactions (ADRs). Categorical variables were compared using the chi-square or Fisher's exact test, and continuous variables were compared using the independent t-test.
RESULTS: A total of 2914 patients were included, of whom 2083 received amikacin, and 831 received fosfomycin. Symptomatic UTI occurred in 6.7% of patients in the amikacin group and 8.2% in the fosfomycin group (p = 0.18). Culture-positive UTI rates were comparable (2.1% vs 2.0%, p = 0.91). Acute kidney injury was significantly more frequent with amikacin (2.6% vs 0.1%, p < 0.001), while gastrointestinal adverse effects were more common with fosfomycin (8.3% vs 2.3%, p < 0.001). Injection-related reactions occurred only in the amikacin group.
CONCLUSIONS: Fosfomycin demonstrated efficacy comparable to amikacin for preventing post-cystoscopy UTI, with a more favorable safety profile. Oral fosfomycin represents a safe and effective alternative to aminoglycosides for prophylaxis before outpatient cystoscopic procedures, particularly in patients at risk for aminoglycoside-related toxicity.
METHODS: This retrospective comparative observational study included adult patients undergoing outpatient CPE at a tertiary care center between October 2024 and November 2025. Patients received either a single intravenous dose of amikacin (15 mg/kg) or a single oral dose of fosfomycin trometamol (3 g) before the procedure, according to institutional practice. The primary outcome was the incidence of symptomatic urinary tract infection (UTI) within 14 days following CPE. Secondary outcomes included culture-positive UTI and adverse drug reactions (ADRs). Categorical variables were compared using the chi-square or Fisher's exact test, and continuous variables were compared using the independent t-test.
RESULTS: A total of 2914 patients were included, of whom 2083 received amikacin, and 831 received fosfomycin. Symptomatic UTI occurred in 6.7% of patients in the amikacin group and 8.2% in the fosfomycin group (p = 0.18). Culture-positive UTI rates were comparable (2.1% vs 2.0%, p = 0.91). Acute kidney injury was significantly more frequent with amikacin (2.6% vs 0.1%, p < 0.001), while gastrointestinal adverse effects were more common with fosfomycin (8.3% vs 2.3%, p < 0.001). Injection-related reactions occurred only in the amikacin group.
CONCLUSIONS: Fosfomycin demonstrated efficacy comparable to amikacin for preventing post-cystoscopy UTI, with a more favorable safety profile. Oral fosfomycin represents a safe and effective alternative to aminoglycosides for prophylaxis before outpatient cystoscopic procedures, particularly in patients at risk for aminoglycoside-related toxicity.